JPMorgan raised the firm’s price target on Oric Pharmaceuticals to $19 from $17 and keeps an Overweight rating on the shares. The analyst also removed the shares from the firm’s Analyst Focus List. The analyst has a “very positive outlook” on the shares, but says the firm’s “choose your own adventure” thesis related to ORIC-114, ORIC-944 and ORIC-533 has now played out with data updates over the course of the past six months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ORIC:
- Oric provides initial Phase 1b data for ORIC-944, 2024 milestones
- ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones
- ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Oric Pharmaceuticals files to sell 12.14M shares of common stock for holders
- Oric Pharmaceuticals price target lowered by $1 at H.C. Wainwright, here’s why
